Hansa Bolsters Financials with SERB Deal, Eyes Growth
Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...
Continue Reading